Abstract | BACKGROUND: PATIENTS AND METHODS: In a total of 55 patients, 38 patients were eligible, consisting the pre-emptive group (N=25) and reactive group (N=13). Acneiform rash and other adverse events were graded according to the CTCAE v4.0. RESULTS: The occurrence of acneiform rash (grade ≥2) was significantly lower in pre-emptive group than in reactive group (44.0% vs. 84.6%, p=0.04). No significant differences in the occurrence of other adverse events were observed between the two groups. Tumor response was not significantly different between the two groups (36.0% vs. 7.7%, OR, 6.75; 95% confidence interval (CI)=0.75-60.76, p=0.12). Mean time to treatment failure was 149.7 days and 110.2 days in the pre-emptive group and reactive treatment group, respectively (HR=0.58; 95% CI= 0.26-1.28, p=0.18). CONCLUSION:
|
Authors | Maya Yamada, Hirotoshi Iihara, Hironori Fujii, Masashi Ishihara, Nobuhisa Matsuhashi, Takao Takahashi, Kazuhiro Yoshida, Yoshinori Itoh |
Journal | Anticancer research
(Anticancer Res)
Vol. 35
Issue 11
Pg. 6175-81
(Nov 2015)
ISSN: 1791-7530 [Electronic] Greece |
PMID | 26504047
(Publication Type: Journal Article)
|
Copyright | Copyright© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved. |
Chemical References |
- Anti-Bacterial Agents
- Antibodies, Monoclonal
- Antineoplastic Agents
- Panitumumab
- Minocycline
|
Topics |
- Acneiform Eruptions
(chemically induced, prevention & control)
- Administration, Oral
- Administration, Topical
- Adult
- Aged
- Aged, 80 and over
- Anti-Bacterial Agents
(therapeutic use)
- Antibodies, Monoclonal
(adverse effects)
- Antineoplastic Agents
(adverse effects)
- Cohort Studies
- Colorectal Neoplasms
(drug therapy, pathology)
- Drug Therapy, Combination
- Exanthema
(chemically induced, prevention & control)
- Female
- Follow-Up Studies
- Humans
- Liver Neoplasms
(drug therapy, secondary)
- Male
- Middle Aged
- Minocycline
(therapeutic use)
- Neoplasm Staging
- Panitumumab
- Prognosis
- Skin Care
|